| Stage | CR | % of rev | PH | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $755M | 100.00% | $5.8B | 100.00% | PH ×7.63 |
| Gross profit | $315M | 41.69% | $2.2B | 39.04% | CR +2.6pp |
| Operating income | $141M | 18.63% | $1.4B | 23.86% | PH +5.2pp |
| Pre-tax income | $126M | 16.72% | $1.3B | 23.28% | PH +6.6pp |
| Net income | $97M | 12.89% | $1.1B | 18.97% | PH +6.1pp |
| Stage | CR | PH | Gap · A − B |
|---|---|---|---|
| Revenue | $755M100.00% | $5.8B100.00% | PH ×7.63 |
| Gross profit | 41.69%$315M | 39.04%$2.2B | CR +2.6pp |
| Operating income | 18.63%$141M | 23.86%$1.4B | PH +5.2pp |
| Pre-tax income | 16.72%$126M | 23.28%$1.3B | PH +6.6pp |
| Net income |
| 12.89%$97M |
| 18.97%$1.1B |
| PH +6.1pp |
None
No disclosed counterparties: CR.